SARS‑CoV‑2, the virus that causes COVID-19, continues to mutate, with some newer strains becoming less responsive to current antiviral treatments like Paxlovid.
Why Do Large B-Cell Lymphoma Patients With High Tumor Mutation Burden Relapse on CAR T-Cell Therapy?
Researchers explored this question at ASH and shared data suggesting genomic instability in tumors with high TMB likely enables them to hide from immune attack.
Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.
With the MiSeq™ i100 Series, Illumina continues to set the highest standards.Advancements in system design, sequencing chemistry, and data analysis deliverthe simplest, fastest benchtop sequencing and ...
In a new trial, patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after ...
The global genomics market is set to expand from USD 47.07 billion in 2025 to USD 85.09 billion by 2030, with a CAGR of 12.6% ...
Cell free RNA diagnostics market is projected to reach US$ 204.5 Mn by 2035, expanding at a CAGR of 14.5% from 2025 to 2035 ...
The next generation sequencing market offers significant opportunities by enhancing the diagnosis and treatment of chronic ...
Spatial RNA medicine combines transcriptomics and RNA therapeutics, mapping gene expression in tissues to enhance precision ...
From enzymes and lipid nanoparticles to large-scale process design, four global innovators redefine RNA-based medicine development and delivery.
However, the causative organism was not identified until 1992 by molecular methods and was initially named Tropheryma ...
The field of genetic epidemiology has been revolutionized by recent advancements in next-generation sequencing technologies, as well as the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback